Abstract
Understanding the molecular mechanisms and the signaling pathways that underlie the pathology of cancer progression is crucial for the development of novel diagnostic and therapeutic tools.
A major common mechanism used by cells to regulate intracellular signal transduction pathways is reversible protein phosphorylation which results in profound changes in cellular responses. This mechanism relies on the coordinated action of two families of proteins: protein kinases and protein phosphatases. Interestingly, there are 3 to 5 times fewer phosphatases than kinases, suggesting that the specificity of substrates is not only due to the variety of the catalytic subunits but also to the diversity of the regulatory subunits. This is particularly true for PhosphoProtein Phosphatase 1 (PPP1) for which more than 200 PPP1 Interacting Proteins (PIPs) have thus far been identified. PIPs can act as targeting subunits, substrates and activity regulators. Many PPP1/PIPs complexes are involved in signaling pathways that regulate cellular growth, cell cycle and apoptosis; processes known to be deregulated in cancer.
This review will describe the cellular pathways, many of which involve PPP1/PIP complexes, that when deregulated lead to cancer. Furthermore, the possibility of PPP1/PIP complexes being considered novel targets to cancer diagnostic and therapy will be addressed.
Keywords: Cancer therapy, phosphatase, PPP1, PPP1 interacting proteins, signaling pathways in cancer.
Current Cancer Drug Targets
Title:Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Volume: 14 Issue: 1
Author(s): Joao Figueiredo, Odete A. B. da Cruz e Silva and Margarida Fardilha
Affiliation:
Keywords: Cancer therapy, phosphatase, PPP1, PPP1 interacting proteins, signaling pathways in cancer.
Abstract: Understanding the molecular mechanisms and the signaling pathways that underlie the pathology of cancer progression is crucial for the development of novel diagnostic and therapeutic tools.
A major common mechanism used by cells to regulate intracellular signal transduction pathways is reversible protein phosphorylation which results in profound changes in cellular responses. This mechanism relies on the coordinated action of two families of proteins: protein kinases and protein phosphatases. Interestingly, there are 3 to 5 times fewer phosphatases than kinases, suggesting that the specificity of substrates is not only due to the variety of the catalytic subunits but also to the diversity of the regulatory subunits. This is particularly true for PhosphoProtein Phosphatase 1 (PPP1) for which more than 200 PPP1 Interacting Proteins (PIPs) have thus far been identified. PIPs can act as targeting subunits, substrates and activity regulators. Many PPP1/PIPs complexes are involved in signaling pathways that regulate cellular growth, cell cycle and apoptosis; processes known to be deregulated in cancer.
This review will describe the cellular pathways, many of which involve PPP1/PIP complexes, that when deregulated lead to cancer. Furthermore, the possibility of PPP1/PIP complexes being considered novel targets to cancer diagnostic and therapy will be addressed.
Export Options
About this article
Cite this article as:
Figueiredo Joao, da Cruz e Silva A. B. Odete and Fardilha Margarida, Protein Phosphatase 1 and Its Complexes in Carcinogenesis, Current Cancer Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/15680096113136660106
DOI https://dx.doi.org/10.2174/15680096113136660106 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hemicellulose from Plant Biomass in Medical and Pharmaceutical Application: A Critical Review
Current Medicinal Chemistry HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network
Inflammation & Allergy - Drug Targets (Discontinued) A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Inhibition of the Tissue Factor Coagulation Pathway
Current Vascular Pharmacology Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews Editorial (Thematic Issue: Bladder Conditions in Pediatric Patients: Genetics and Genomics)
Current Genomics Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Development and Applications of Optical Imaging Techniques in Cancer Diagnosis: Diffuse Optical Tomography and Microendoscopy
Current Medical Imaging Reflux Extraction and Column Chromatography for Rosmarinic Acid- Rich Fraction from Orthosiphon stamineus
The Natural Products Journal Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets